Patents by Inventor Denzil Bernard

Denzil Bernard has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20210198237
    Abstract: The present disclosure provides compounds represented by Formula I: and the pharmaceutically acceptable salts, hydrates, and solvates thereof, wherein R2, R3a, R3b, A, G, X, and Y are as defined as set forth in the specification. The present disclosure also provides compounds of Formula I for use to treat a condition or disorder responsive to menin inhibition such as cancer.
    Type: Application
    Filed: November 23, 2020
    Publication date: July 1, 2021
    Inventors: Shaomeng Wang, Angelo Aguilar, Ke Zheng, Shilin Xu, Tianfeng Xu, Denzil Bernard, Liyue Huang
  • Patent number: 10899738
    Abstract: The present disclosure provides compounds by Formula (I): (Formula (I)) and the pharmaceutically acceptable salts, hydrates, and solvates thereof, wherein R2, R3a, R3b, A, G, X, and Y are as defined as set forth in the specification. The present disclosure also provides compounds of Formula (I) for use to treat a condition or disorder responsive to menin inhibition such as cancer.
    Type: Grant
    Filed: May 2, 2017
    Date of Patent: January 26, 2021
    Assignee: THE REGENTS OF THE UNIVERSITY OF MICHIGAN
    Inventors: Shaomeng Wang, Angelo Aguilar, Ke Zheng, Shilin Xu, Tianfeng Xu, Denzil Bernard, Liyue Huang
  • Publication number: 20200109167
    Abstract: Compounds of formula (I) as inhibitors of DCN1 and compositions containing the same are disclosed. Methods of using the DCN1 inhibitors in the treatment of diseases and conditions wherein inhibition of DCN1 provides a benefit, like oxidative stress-related diseases and conditions, neurodegenerative diseases and conditions, metabolic disorders, and muscular nerve degeneration, also are disclosed.
    Type: Application
    Filed: March 28, 2018
    Publication date: April 9, 2020
    Inventors: Shaomeng Wang, Haibin Zhou, Jianfeng Lu, Liu Liu, Yi Sun, Denzil Bernard
  • Publication number: 20190152947
    Abstract: The present disclosure provides compounds by Formula (I): (Formula(I)) and the pharmaceutically acceptable salts, hydrates, and solvates thereof, wherein R2, R3a, R3b, A, G, X, and Y are as defined as set forth in the specification. The present disclosure also provides compounds of Formula (I) for use to treat a condition or disorder responsive to menin inhibition such as cancer.
    Type: Application
    Filed: May 2, 2017
    Publication date: May 23, 2019
    Inventors: Shaomeng Wang, Angelo Aguilar, Ke Zheng, Shilin Xu, Tianfeng Xu, Denzil Bernard, Liyue Huang
  • Patent number: 9233086
    Abstract: Peptidomimetics that inhibit the interaction between MLL1 and WDR5 are disclosed. Methods of inhibiting MLL1 activity and methods of treating cancers also are disclosed.
    Type: Grant
    Filed: June 14, 2011
    Date of Patent: January 12, 2016
    Assignee: THE REGENTS OF THE UNIVERSITY OF MICHIGAN
    Inventors: Shaomeng Wang, Hacer Karatas, Yali Dou, Elizabeth Townsend, Denzil Bernard
  • Patent number: 8980838
    Abstract: Cyclic peptidomimetics that inhibit the interaction between MLL1 and WDR5 are disclosed. Methods of inhibiting MLL1 activity and methods of treating cancers also are disclosed.
    Type: Grant
    Filed: November 27, 2012
    Date of Patent: March 17, 2015
    Assignee: The Regents of the University of Michigan
    Inventors: Shaomeng Wang, Hacer Karatas, Yali Dou, Elizabeth Townsend, Denzil Bernard, Fang Cao
  • Publication number: 20110312997
    Abstract: Peptidomimetics that inhibit the interaction between MLL1 and WDR5 are disclosed. Methods of inhibiting MLL1 activity and methods of treating cancers also are disclosed.
    Type: Application
    Filed: June 14, 2011
    Publication date: December 22, 2011
    Inventors: Shaomeng Wang, Hacer Karatas, Yali Dou, Elizabeth Townsend, Denzil Bernard